Effects of Melatonin Administration on Cytokine Production in Patients With Advanced Solid Tumors

Neri, B; Brocchi, A; Carossino, Anna Maria; Cini-Neri, G; Gemelli, M T; Tommasi,; Cagnoni, M

doi:10.3892/or.2.1.45

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liebmann/Wölfler/Felsner/Hofer/ Schauenstein Furthermore, melatonin was reported to reduce the tu mor growth in human patients suffering from advanced lung or colorectal cancer or brain metastases [27], to potentiate the therapeutic effect o f interleukin 2 (IL-2) treatment [28,29], and to protect against the negative side effects o f IL-2 treatment in non-small cell lung cancer [30], The possible clinical relevance o f melatonin in neoplastic diseases was recently reviewed by Webb and Puig-Domingo [31]. The mechanism o f action o f melatonin against tumor growth in vivo is multifactorial, and may partially lie in stimulatory effects on immune functions [32], It was recently shown that a 30-day melatonin treatment in patients with advanced solid tumors led to increased serum levels o f circulating tu mor necrosis factor-a, IL-2, and y-interferon (y-IFN) by 28, 51, and 41%, respectively, as compared with pretreatment levels [33]. Direct antiproliferative effects o f melatonin on malignant cells in vitro have been reported, but remained contradictory [for review, see 34,35],…”

Section: Introductionmentioning

confidence: 99%

Melatonin and the Immune System

Liebmann

Wölfler

Felsner

et al. 1997

Int Arch Allergy Immunol

144

View full text Add to dashboard Cite

In recent years, melatonin, i.e. the major endocrine product of the pineal gland, was investigated as to its possible regulatory role in the communication between the neuroendocrine and the immune systems. First indications that melatonin may be an endocrine immunomodulator came from early reports about antitumor effects in animals and humans. Since then evidence has accumulated suggesting that melatonin – as a well-preserved molecule during evolution – is indeed involved in the feedback between neuroendocrine and immune functions. At present we begin to discover molecular mechanisms, by which melatonin affects cellular functions in general, and from the variety of possible direct and indirect interactions it appears that melatonin may play a complex physiological role in neuroimmunomodulation. In this article we want to give a critical review of the numerous reports on melatonin influencing immune functions, and to discuss the possible different mechanisms of action, which were suggested recently.

show abstract

Section: Introductionmentioning

confidence: 99%

Melatonin and the Immune System

Liebmann

Wölfler

Felsner

et al. 1997

Int Arch Allergy Immunol

144

View full text Add to dashboard Cite

show abstract

“…MLT enhances the activity of tumoricidal cells and potentiates the production and release of some cytokines, tumor necrosis factor, interleukin-2, and interferon-␥ (Neri et al, 1995). MLT injection in the late light phase, but not in the early light phase, increases the serum interferon-␥ level (Champney et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

Chronopharmacology of Melatonin in Mice to Maximize the Antitumor Effect and Minimize the Rhythm Disturbance Effect

Akagı

Ushinohama

Ikesue

et al. 2003

J Pharmacol Exp Ther

View full text Add to dashboard Cite

The influence of dosing time on the antitumor effect and the rhythm disturbance effect of melatonin (MLT) was investigated in ICR male mice under a light/dark (12:12) cycle. In tumorbearing mice, the antitumor effect of MLT (1 mg/kg intraperitoneal) was most effective in the dark phase; and the rhythm disturbance effect of MLT on the locomotor activity was more serious in the light phase than in the dark phase. The antitumor effect and the rhythm disturbance effect of MLT increased when the specific binding of MLT receptor in target tissues, tumor or suprachiasmatic nucleus, increased and they decreased when the level decreased. Furthermore, because luzindole, an MT 1 and MT 2 blocker, caused the antitumor effect or rhythm disturbance effect of MLT to decrease, it is suggested that the time-dependent change of the pharmacological effects of MLT were influenced by that of MLT receptor(s) function. On the other hand, there was no significant dosing time-dependent change of MLT concentration in tumor or brain after injection. Thus, the pharmacokinetic factor does not seem to contribute to the dosing time-dependent effect of MLT. These results suggest that by choosing the most suitable dosing time for MLT, the efficacy of the drug can be increased, and the toxicity of the drug can be decreased in certain experimental and clinical situations.

show abstract

Effects of Melatonin Administration on Cytokine Production in Patients With Advanced Solid Tumors

Cited by 2 publications

References 0 publications

Melatonin and the Immune System

Melatonin and the Immune System

Chronopharmacology of Melatonin in Mice to Maximize the Antitumor Effect and Minimize the Rhythm Disturbance Effect

Contact Info

Product

Resources

About